JP7008920B2 - 血漿カリクレイン阻害剤および遺伝性血管浮腫発作を予防するためのその使用 - Google Patents

血漿カリクレイン阻害剤および遺伝性血管浮腫発作を予防するためのその使用 Download PDF

Info

Publication number
JP7008920B2
JP7008920B2 JP2017549388A JP2017549388A JP7008920B2 JP 7008920 B2 JP7008920 B2 JP 7008920B2 JP 2017549388 A JP2017549388 A JP 2017549388A JP 2017549388 A JP2017549388 A JP 2017549388A JP 7008920 B2 JP7008920 B2 JP 7008920B2
Authority
JP
Japan
Prior art keywords
antibody
hae
pharmaceutical composition
administered
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017549388A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018514510A5 (OSRAM
JP2018514510A (ja
Inventor
チユン，ヤン
アデルマン，ブルト
ジェイ． セクストン，ダニエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57005262&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7008920(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2018514510A publication Critical patent/JP2018514510A/ja
Publication of JP2018514510A5 publication Critical patent/JP2018514510A5/ja
Priority to JP2021204200A priority Critical patent/JP7309836B2/ja
Application granted granted Critical
Publication of JP7008920B2 publication Critical patent/JP7008920B2/ja
Priority to JP2023110592A priority patent/JP2023130442A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017549388A 2015-03-30 2016-03-30 血漿カリクレイン阻害剤および遺伝性血管浮腫発作を予防するためのその使用 Active JP7008920B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021204200A JP7309836B2 (ja) 2015-03-30 2021-12-16 血漿カリクレイン阻害剤および遺伝性血管浮腫発作を予防するためのその使用
JP2023110592A JP2023130442A (ja) 2015-03-30 2023-07-05 血漿カリクレイン阻害剤および遺伝性血管浮腫発作を予防するためのその使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562140277P 2015-03-30 2015-03-30
US201562140289P 2015-03-30 2015-03-30
US62/140,277 2015-03-30
US62/140,289 2015-03-30
US201562214293P 2015-09-04 2015-09-04
US62/214,293 2015-09-04
PCT/US2016/024921 WO2016160926A1 (en) 2015-03-30 2016-03-30 Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021204200A Division JP7309836B2 (ja) 2015-03-30 2021-12-16 血漿カリクレイン阻害剤および遺伝性血管浮腫発作を予防するためのその使用

Publications (3)

Publication Number Publication Date
JP2018514510A JP2018514510A (ja) 2018-06-07
JP2018514510A5 JP2018514510A5 (OSRAM) 2019-05-09
JP7008920B2 true JP7008920B2 (ja) 2022-01-25

Family

ID=57005262

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017549388A Active JP7008920B2 (ja) 2015-03-30 2016-03-30 血漿カリクレイン阻害剤および遺伝性血管浮腫発作を予防するためのその使用
JP2021204200A Active JP7309836B2 (ja) 2015-03-30 2021-12-16 血漿カリクレイン阻害剤および遺伝性血管浮腫発作を予防するためのその使用
JP2023110592A Pending JP2023130442A (ja) 2015-03-30 2023-07-05 血漿カリクレイン阻害剤および遺伝性血管浮腫発作を予防するためのその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021204200A Active JP7309836B2 (ja) 2015-03-30 2021-12-16 血漿カリクレイン阻害剤および遺伝性血管浮腫発作を予防するためのその使用
JP2023110592A Pending JP2023130442A (ja) 2015-03-30 2023-07-05 血漿カリクレイン阻害剤および遺伝性血管浮腫発作を予防するためのその使用

Country Status (14)

Country Link
US (2) US20180298110A1 (OSRAM)
EP (2) EP3916020A1 (OSRAM)
JP (3) JP7008920B2 (OSRAM)
KR (3) KR102607829B1 (OSRAM)
CN (1) CN107614532A (OSRAM)
AU (3) AU2016243160B2 (OSRAM)
BR (1) BR112017020864A2 (OSRAM)
CA (1) CA2979713A1 (OSRAM)
CO (1) CO2017009404A2 (OSRAM)
EA (1) EA201792161A1 (OSRAM)
HK (1) HK1250995A1 (OSRAM)
IL (2) IL254292B1 (OSRAM)
MX (2) MX2017012423A (OSRAM)
WO (1) WO2016160926A1 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2521568T3 (pl) 2010-01-06 2019-03-29 Dyax Corp. Białka wiążące kalikreinę osocza
KR102502293B1 (ko) 2011-01-06 2023-02-21 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
CA2906624A1 (en) 2013-03-15 2014-09-25 Dyax Corp. Anti-plasma kallikrein antibodies
JP6845012B2 (ja) 2014-01-21 2021-03-17 ダイアックス コーポレーション 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用
KR20230109785A (ko) 2014-03-27 2023-07-20 다케다 파머수티컬 컴패니 리미티드 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법
WO2017100679A1 (en) * 2015-12-11 2017-06-15 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
AU2017325986B2 (en) * 2016-09-16 2023-12-14 Takeda Pharmaceutical Company Limited Metabolite biomarkers for diseases associated with the contact activation system
JP7210540B2 (ja) 2017-08-04 2023-01-23 武田薬品工業株式会社 血漿カリクレインの阻害剤およびその使用
AU2019227866A1 (en) * 2018-02-28 2020-10-01 Attune Pharmaceuticals, Inc. Treatment of hereditary angioedema
WO2019166572A1 (en) * 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
EP3843840A1 (en) * 2018-08-30 2021-07-07 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
CN114166924B (zh) * 2021-12-03 2024-11-22 中国医学科学院北京协和医院 尿液蛋白标志物在诊断遗传性血管水肿中的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006501168A (ja) 2002-06-14 2006-01-12 メディミューン，インコーポレイテッド 安定化した抗ｒｓｖ抗体液体製剤
WO2013186700A1 (en) 2012-06-12 2013-12-19 Novartis Ag Antibody formulation
JP2014515763A (ja) 2011-05-02 2014-07-03 ミレニアム ファーマシューティカルズ， インコーポレイテッド 抗α４β７抗体のための製剤
WO2014152232A2 (en) 2013-03-15 2014-09-25 Dyax Corp. Anti-plasma kallikrein antibodies

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
EP0739355B1 (en) 1994-01-11 2004-09-08 Dyax Corporation Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
ATE477020T1 (de) 2002-06-07 2010-08-15 Dyax Corp Prevention und verringerung von ischemia
PL2521568T3 (pl) * 2010-01-06 2019-03-29 Dyax Corp. Białka wiążące kalikreinę osocza
KR102502293B1 (ko) * 2011-01-06 2023-02-21 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
HUE041332T2 (hu) * 2013-01-20 2019-05-28 Dyax Corp Bradikinin-közvetített rendellenességek értékelése és kezelése
KR20140119396A (ko) * 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
KR20250066486A (ko) * 2013-10-21 2025-05-13 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법
JP6845012B2 (ja) * 2014-01-21 2021-03-17 ダイアックス コーポレーション 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006501168A (ja) 2002-06-14 2006-01-12 メディミューン，インコーポレイテッド 安定化した抗ｒｓｖ抗体液体製剤
JP2014515763A (ja) 2011-05-02 2014-07-03 ミレニアム ファーマシューティカルズ， インコーポレイテッド 抗α４β７抗体のための製剤
WO2013186700A1 (en) 2012-06-12 2013-12-19 Novartis Ag Antibody formulation
WO2014152232A2 (en) 2013-03-15 2014-09-25 Dyax Corp. Anti-plasma kallikrein antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ann Allergy Asthma Immunol，2014年，Vol.113，pp.460-466

Also Published As

Publication number Publication date
US20180298110A1 (en) 2018-10-18
KR20170135885A (ko) 2017-12-08
EP3916020A1 (en) 2021-12-01
EA201792161A1 (ru) 2018-04-30
KR102799778B1 (ko) 2025-04-28
KR20250057946A (ko) 2025-04-29
BR112017020864A2 (en) 2018-07-10
IL305207A (en) 2023-10-01
EP3286226A4 (en) 2018-12-05
AU2016243160A1 (en) 2017-10-05
JP2023130442A (ja) 2023-09-20
JP2022037131A (ja) 2022-03-08
HK1250995A1 (zh) 2019-01-18
US20220169749A1 (en) 2022-06-02
CA2979713A1 (en) 2016-10-06
NZ735659A (en) 2023-08-25
KR102607829B1 (ko) 2023-12-01
CO2017009404A2 (es) 2018-03-09
AU2025271115A1 (en) 2025-12-18
JP2018514510A (ja) 2018-06-07
WO2016160926A1 (en) 2016-10-06
JP7309836B2 (ja) 2023-07-18
IL254292A0 (en) 2017-10-31
MX2023010206A (es) 2023-09-11
NZ774543A (en) 2024-04-26
MX2017012423A (es) 2018-01-26
AU2022203180B2 (en) 2025-09-11
AU2022203180A1 (en) 2022-06-02
EP3286226A1 (en) 2018-02-28
KR20230164767A (ko) 2023-12-04
IL254292B1 (en) 2025-09-01
AU2016243160B2 (en) 2022-02-24
CN107614532A (zh) 2018-01-19

Similar Documents

Publication Publication Date Title
AU2020244370B2 (en) Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
JP7008920B2 (ja) 血漿カリクレイン阻害剤および遺伝性血管浮腫発作を予防するためのその使用
AU2019328324B2 (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
KR102903403B1 (ko) 혈장 칼리크레인 결합 단백질 및 유전성 혈관부종을 치료하는 데 있어서의 이의 용도
HK40057855A (en) Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
HK40064044A (en) Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
EA046649B1 (ru) Ингибиторы калликреинов плазмы и их применение для профилактики приступа наследственного ангионевротического отека
NZ735659B2 (en) Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190327

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200417

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200622

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210601

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211116

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20211203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211216

R150 Certificate of patent or registration of utility model

Ref document number: 7008920

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250